Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Looking like a Gap up this morning!
Thank You Redrock!!
Been Loading more this morning
Agreed, just added another 523k!!
Nice 2 mil close at 12!!
Lumpy9200, I'm no expert on the matter but the "Grant Stage" of the process is explained on this Patent and Trade Mark Attorney website.
https://www.dehns.com/cms/document/grant_stage_of_european_patents.pdf
"Once the Examining Division is satisfied that an application complies with all the requirements of the European Patent Convention (EPC), the applicant is notified of the intention of the European Patent Office (EPO) to grant a patent."
The company may be quite but their DRUG Mipsagargin is shouting possiblities
The "D" is off.
We are reporting Pink Current Information.
https://www.otcmarkets.com/stock/NSPX/overview
L2 is extremely thin.
Waiting on Patent Application Review:
Application Number: 15/100,780 for:
PRODUCTION OF THAPSIGARGINS BY THAPSIA CELL SUSPENSION CULTURE
https://portal.uspto.gov/pair/PublicPair
More Published articles and drug website updates for Mipsagargin:
Published: 28 October 2019:
https://www.nature.com/articles/s41598-019-51894-3
Modified 10/26/2019:
https://pubchem.ncbi.nlm.nih.gov/compound/24772106 -
First Substance UPDATE: 9/23/2019
https://pubchem.ncbi.nlm.nih.gov/substance/385757790
Drug created on October 20, 2016 14:50 / Updated on September 02, 2019 19:31
https://www.drugbank.ca/drugs/DB11813 - Mipsagargin:
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Updated Oct. 2019:
https://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=Q032I35QMX
Cant seem to pull up this website:
" http://vuracehe.ga/swedish-orphan-biovitrum-ab-stockholm.html "
It came up in a search this morning related to Mipsagargin. SOBI "Swedish Orphan Biovitrum AB" is a very lucrative company.
Connection - From NSPX SEC filing Form 10k for fiscal year ended Dec 2016 - "Bo Jesper Hansen, MD, PhD joined our board in August of 2010. From January of 2010 until May 2016, Dr. Hansen was the Executive Chairman of the Board of Swedish Orphan Biovitrum AB (NASDAQ OMX, STO: SOBI)"
https://www.sec.gov/Archives/edgar/data/1421204/000161577417001721/s105817_10k.htm
Royal Society of Chemistry -"In addition to its physiological importance, SERCA is the
target for Mipsagargin (G202), a drug candidate for treatment
of prostate cancer and hepatocellular carcinoma derived from
the natural product thapsigargin (TG)"
https://pubs.rsc.org/en/content/articlelanding/2019/cp/c9cp04736k#!divAbstract
The article was received on 26 Aug 2019, accepted on 17 Sep 2019 and first published on 17 Sep 2019
$NSPX STONGER
2015 Thapsigargin Study just Accepted and Published, Sept 29th, 2019 in “Oxford Academic Annals of Botany:”
https://academic.oup.com/aob/article/doi/10.1093/aob/mcz151/5575980/
**** ACKNOWLEDGEMENTS: The HPLC standards were extracted and purified under the direction of Søren Brøgger Christensen
Article written Sept. 30th, 2019 about it in Botany One
https://www.botany.one/2019/09/what-factors-make-a-deadly-carrot-so-dangerous/
Wayback site date capture shows that Dr. Christensen was a founding member and he continues to further the study of Thapsigargin
https://web.archive.org/web/20161009012602/http://www.inspyrtx.com/team/scientific-advisory-board
******Dr. Christensen has co-authored over 160 scientific publications and is co-inventor on several key patents in Inspyr's intellectual property portfolio.
$NSPX STRONGER
Why are you a moderator of this board?
Moderators should have a vested interest in the stock they moderate.
You have zero interest in NSPX besides to post that this company has debt.
Which means you only flip and/or short for the Benefit of Yourself.
Which means you prey and take advantage of others.
There are special places for certain people......
$NSPX STRONGER
Just want to clear something up and confirm your view.
Information is key! Anyone can ask me a question and will get an answer with verifiable information. I like to help people.
You only care about numbers and have no interest in this company's actual operations or future.
I continue to post verifiable Published DD in regards to the company's past/present/future.
You continue to say the same thing, that this company has debt and needs to pay it off. You post no break down of your numbers. You change your numbers every other week. You say if someone wants to find the numbers they need to do the DD themselves. You post nothing to backup your unfounded numbers. One post you said the company was in 8 million debt then 11 million debt then 60 million debt.
*******************************************************
Every company has debt and needs to come up with a plan to pay it off.
They are on that higher end of debt as stated in their Sept. 13th, 2019 filings: "We have incurred losses since inception and have an accumulated deficit of $61 million as of June 30, 2019".
Since their inception... BioTech company with ONLY 61 million in debt since 2003(Inception), Sounds like a BioTech company for over 16 years that does not waste money to me.. 61 million is high for 5 years but extremely low for 16 years
https://www.sec.gov/Archives/edgar/data/1421204/000121390019017937/f10q0619_inspyrtherapeutics.htm
NSPX has come up with a plan, followed through, with their best available impact on shareholders. No one likes an RS. That goes without saying.
$NSPX has no sales. I agree
$NSPX is a BioTech company. What BioTech company does not have literally $hundreds of millions of dollars in Debt.
$NSPX has a very important drug "Mipsagargin" that requires further investigation. As stated in their latest Published Clinical Phase II Trials update on June 17th, 2019.
$NSPX cannot move forward without a commercially synthesized supply of Thapsigargin. This is continually being pushed by Phyton BioTech "Global Leaders in Plant Cell Fermentation".
$NSPX played it right over the last 2 years. Minimize new debt. Wait for Thapsigargin to be commercially synthesized.
Unfortunately they need to pay for debts which are coming due. Thus the need for the RS to raise money.
To only look at the numbers of this Company is a great disadvantage and dishonest attempt to drive a Share Price down.
$NSPX
$NSPX has a legit drug, where it goes only longs will find out. I’ve posted an email thread from a Brazilian University Published researcher that agreed that the commercial supply was a big problem. This company needs funding, getting current, RS was a means to that.
Phyton BioTech resubmitted, Sept. 30th, 2019, an updated Oral Hearing Patent request for Synthesizing "PRODUCTION OF THAPSIGARGINS BY THAPSIA CELL SUSPENSION CULTURE".
Once they get this patent approved they will solve the Commercial Supply issues. Its been ongoing Since 2016.... Coincidentally around the same time $NSPX started getting quite.
https://portal.uspto.gov/pair/PublicPair -
Application Number - 15/100780
Think about it...
Started getting current in April 2019
June 17th, 2019 Updated Phase II report Published, no hype/PR.. Just Published Medically and Scientifically. https://www.mdpi.com/2072-6694/11/6/833
September 13th, 2019 They become fully reported..
October 1st, 2019 minimal RS..
October 3, 2019 Commercial Supply issue on verge of being resolved with the excepted review of the Patent submission.
During this entire time the only money the company has spent was on Getting SEC updated and OTC Current.
There are no fake/misleading/hype/crappy PR's promising anything.
$NSPX STRONGER
I still think there is something else brewing.
They needed funding to advance their Drug’s progress.
I’m still fully looking to the outcome this years process of getting financially current, which is no easy task for any company.
Again going back to they aren’t wasting money.
$NSPX STRONGER
Please elaborate on this statement!
Any verifiable links?
Because that would be awesome!!
$NSPX STRONGER
We have 1.4 mil bid support at .0035 this morning!
Volume coming!
$NSPX STRONGER
There was a huge 1.4 mil bid at the end of the day yesterday at .0035.
Keeping an eye on this today!
$NSPX STRONGER
1.4 mil bid! Volume coming
Just a reminder that on June 17th, 2019 updated Phase II study information was published *NOT PR'ed*.
The Conclusion of that published article was:
"These findings warrant a larger clinical study to further characterize the activity of mipsagargin in advanced HCC."
https://www.mdpi.com/2072-6694/11/6/833/htm
Publication Title:
"A Phase II, Multicenter, Single-Arm Study of Mipsagargin (G-202) as a Second-Line Therapy Following Sorafenib for Adult Patients with Progressive Advanced Hepatocellular Carcinoma"
The timing of a Published Positive Clinical Trial Update and the company getting current makes me think something is in the works!
$NSPX STRONGER
NSPX Stop Sign gone on OTC Markets
https://www.otcmarkets.com/stock/NSPX/overview
One more!
$NSPX STRONGER
Journal of The American Chemical Society
**Publication Date August 25th, 2019
https://pubs.acs.org/doi/pdf/10.1021/jacs.9b08001
Discusses the synthesis of Thapsigargin (Mipsagargin).
***"Many of these natural products, particularly those with
cis-fused lactones, have remained inaccessible by synthesis,
and the most complex members (i.e. trilobolide/thapsigargin type) have served as grand challenges to the field of total
synthesis for nearly two decades."
"Herein we detail the evolution of a synthetic program aimed at
synthesizing multiple, diverse guaianolide members,"
The question I am always asking during my DD research....
Why do they continue to try to synthesis this?
Now I'm adding to that question "for about 2 decades"
Scientists around the World would not waste 2 decades of research on something that is not worth anything.
GMAN since your mostly in Cryptos..
1. Did you get in when it was trading in Pennies or Dollars?
2. How long did you hold any of it from the beginning?
Think about it!!
Good things take awhile.
I'm hoping your not near sighted with NSPX.
$NSPX STRONGER
#NSPX STRONGER
Next update(s) from Inspyr Therapeutics will be before/on/around September 30th, 2019.
It will be in the form of Financials.
Over the last 4 months Inspyr Therapeutics has been catching up on the past 2 years of Financials to become current. They are now just 2 Quarters left to become fully reporting. These last 2 10q's can be dropped at any time between now and September 30th, 2019
On May 22nd, 2019 Inspyr Therapeutics released Two 10q's less then a month after 2017's 10K was released April 26th, 2019.
2018's 10K was released on August 6th, 2019
https://www.sec.gov/cgi-bin/browse-edgar?company=INSPYR+THERAPEUTICS&owner=exclude&action=getcompany
https://www.sec.gov/Archives/edgar/data/1421204/000121390019014714/f10k2018_inspyrtherapeutics.htm
Section F-21
** NOTE 15 – SUBSEQUENT EVENTS -
"extended the maturity date of such debentures until September 30, 2019"
How so Gman??
No fluffy PRs to make you feel good about your lack of DD??
Here’s more DD to help you over this beautiful weekend in Philly!!
Continued Published Research - Medicinal Chemistry Research September 2019 - Springer Link
ProDrug $MIPSAGARGIN
https://link.springer.com/article/10.1007/s00044-019-02385-7
$NSPX STRONGER
#NSPX STRONGER
You cant argue with Independent Research.
The Research World is expecting this to go to Phase III..
Reference [89] relates to Mipsagargin..
They state "Expected for Phase III randomized controlled trial".
"The EGCG is in Phase II trial for the treatment of acute radiation-
induced esophagitis in stage III lung cancer results in an effective
method and has been expected for a Phase III randomized controlled
trial [[86], [87], [88], [89], [90]]."
August 2019 - https://www.sciencedirect.com/science/article/pii/S1043661818320218
Something is brewing with all this continued Research being Published and the company getting current.
$NSPX STRONGER
#NSPX STRONGER
WAS looking to jump into this but.....
Both dumped about 16.5% of their holdings between June 30th, 2018 and June 30th, 2019
James Gilbert dumped 16.43% of his stock, 4,107,500
William Snyder dumped 16.5% of his stock, 45,375,000
Thats over 49 million shares dumped by 2 insiders
Which is just under 10% of the total authorized shares of 500 million.
https://backend.otcmarkets.com/otcapi/company/financial-report/199482/content - June 30th, 2018
Section 8) Officers, Directors, and Control Persons
JAMES GILBERT IS THE BENEFICIAL OWNER OF 7.3% OF THE COMMON STOCK.
WILLIAM SNYDER IS THE BENEFICIAL OWNER OF 80% OF THE COMMON STOCK.
https://backend.otcmarkets.com/otcapi/company/financial-report/226842/content June 30th, 2019
Section 7) Officers, Directors, and Control Persons
JAMES GILBERT IS THE BENEFICIAL OWNER OF 6.1% OF THE COMMON STOCK.
WILLIAM SNYDER IS THE BENEFICIAL OWNER OF 66.8% OF THE COMMON STOCK.
Who else thinks this is a huge sign of confidence for Inspyr Therapeutics $NSPX
Form 10-Q Stemline Therapeutics Inc - STML
Quarterly report [Sections 13 or 15(d)]
Published: 2019-08-06 16:35:48
https://sec.report/Document/0001104659-19-044314/
"We expect any product candidate that we are able to commercialize will compete with products from other companies in the biotechnology and pharmaceutical industries. For example, there are a number of biopharmaceutical companies focused on developing therapeutics with which we may potentially compete including Astellas Pharma U.S., Inc., Bayer AG, Bionomics Limited, Blueprint Medicines Corp., Boehringer Ingelheim GmbH, Celldex Therapeutics, Inc., Eli Lilly and Co., Ignyta, Inc. (a Roche company), Inspyr Therapeutics, Inc., Geron Corp., GlaxoSmithKline plc, Macrogenics Inc., Micromet, Inc. (an Amgen, Inc. company), OncoMed"
Agreed, No employees, which means no overhead adding to existing liabilities.
Its pursuit of Mispagargin has been continual as stated in their Financials and shown via multiple websites of Published Peer-Reviewed Articles I've been posting since the beginning of this year.
https://www.sec.gov/Archives/edgar/data/1421204/000121390019014714/f10k2018_inspyrtherapeutics.htm
Section 9
"We depend upon independent contract research organizations, investigators and collaborators, such as universities and medical institutions"
$NSPX STRONGER
#NSPX STRONGER
More peer reviewed research regarding Mipsagargin Published August 12th, 2019
Nothing to believe in but Scientific and Medical Research!
https://www.dovepress.com/thapsigargin-induces-apoptosis-in-adrenocortical-carcinoma-by-activati-peer-reviewed-fulltext-article-DDDT
https://doi.org/10.2147/DDDT.S209947
As the saying goes "Follow the Money!!"
$NSPX STRONGER
#NSPX STRONGER
Good Luck
They are continuing to save money and benefit from partnerships like Ridgeway Therapeutics in regards to "Adenosine Receptor Antagonists"
Section 23 -
"Continue development of anti-cancer agents with partner company,
Ridgeway Therapeutics, Inc."
"We are also working on developing IND approved studies for our
adenosine receptor technology platform."
Yesterday's 10k Section 15:
"While our shareholders have approved a reverse stock split in amount not less than 1-for-2 and not more than 1-for-500 at the discretion of the Board until December 31, 2019, no such additional reverse stock split has taken place."
https://www.sec.gov/Archives/edgar/data/1421204/000121390019014714/f10k2018_inspyrtherapeutics.htm
FlyersFan, what is different from yesterdays 10k release and the previous 3 - 10Q's and the previous 10k for 2017 in those 13 pages?
From my point of view it is the same information, that they are REQUIRED to state, since they are trying to get current.
I'm focusing my attention on actual new information -
Yesterdays 10k (near the bottom), section F-21 / Notice 15 Subsequent Events:
"Effective July 5, 2019, Sabby Healthcare Master Fund, Ltd and Sabby Volatility Warrant Master Fund, Ltd. waived certain events of default under debentures issued in our July 2018 debenture offering and September 2017 debenture offering (collectively, the “Debenture Offerings”) and extended the maturity date of such debentures until September 30, 2019 in exchange for the issuance of $154,000 in new debentures with substantially the same terms as those issued in our Debenture Offerings."
FlyersFan - Why would Sabby extend this deadline?
Sabby doesnt throw money away they make money and they believe in what this company has to offer.
piecing some things together:
https://phytonbiotech.com/latest-news/
https://phytonbiotech.com/ingenol-3-angelate-patent/ - June 27th, 2019
World Academy of Science, Engineering and Technology
International Journal of Medical and Health Sciences
Vol:11, No:6, 2017
https://waset.org/pdf/books/?id=70327&pageNumber=141
Cant ignore the time it takes to synthesize these compounds (and patent).
Phyton was working on Ingenol-3-angelate since 2017 using PCF (Plant Cell fermentation).
I'm gonna be keeping an on Phyton Biotech's advancement and filing of patent information in regards to Mipsagargin/G202!!
Once Phyton releases this information..........
$NSPX STRONGER
#NSPX STRONGER
Anonymoose, They have multiple Patents, one that specifically has a Orphan drug status called #Mipsagargin.
The main thing holding this company back is that they can not move forward with Phase III Clinical Trials until the Scientific community is able to synthesize their Patent Drug "Mipsagargin" for commercial use.
I have posted continued DD, backed up by websites from all over the world, that shows it is being actively advanced. These website are Scientific/Nature/Medical/Cancer Peer reviewed articles.
As stated in its most recent attempts at getting current they explain that they are working in collaboration with Research Organizations, Universities and Medical institutions:
https://www.sec.gov/Archives/edgar/data/1421204/000121390019010762/f10q0918_inspyrtherape.htm
Section 33 of the 10q (mulitiple previous 10q's and 10K) submitted on June 16th, 2019 states
**** "We depend upon independent contract research organizations, investigators and collaborators, such as universities and medical institutions, to conduct our pre-clinical and clinical studies. These individuals and/or entities are not our employees and we cannot control the amount or timing of resources that they devote to our programs. These third parties may not assign as great a priority to our programs or pursue them as diligently as we would if we were undertaking such programs ourselves."
This company has only 1 Employee on a limited basis due to the hold up of synthesizing their Patented drug Mipsagargin. The rest are board members that are Doctor's and Professor's that work at the Universities and Medical Institutions they are collaborating with.
Check out my Previous Posts
#7874 - Top 10 about the company
#8857 - Updated Phase II Clinical Trial data release June 17th, 2019.
They are leveraging their control over their Patents.
Science Always WINS
$NSPX STRONGER
#NSPX STRONGER
Mipsagargin is Patented.. Any advancements that the 3rd Party's/Contractors/Universities/collaborators come up with is protected by the Patents.
This is why i keep saying they arent wasting money on employee's, offices, or any type of overhead. They are letting others advance the drug without accumulating additional debt.
Mipsagargin continues to be studied.
Section 33 of the 10q (mulitiple previous 10q's and 10K) submitted on June 16th, 2019 states ****We depend upon independent contract research organizations, investigators and collaborators, such as universities and medical institutions, to conduct our pre-clinical and clinical studies. These individuals and/or entities are not our employees and we cannot control the amount or timing of resources that they devote to our programs. These third parties may not assign as great a priority to our programs or pursue them as diligently as we would if we were undertaking such programs ourselves.
Website updated about 4 hours ago - Drug Target Mipsagargin.
https://www.genome.jp/dbget-bin/www_bget?hsa+489
Asian Market has the highest cancer rate that Mipsagargin is targeting.
This website is the Japan version.
Dont sleep on this one.
When they finally release current updates including Financials, drug updates, pipelines, partners your gonna see this run.
$NSPX STRONGER
Agreed, yesterday’s volume hasn’t been that high in almost 2 months!
Filings or company update would be a major catalyst for PPS!
$NSPX STRONGER
No reason to
1. get caught up with financials.
2. publish updated Clinical Trials information
If you aren’t attempting to go somewhere!
$NSPX STRONGER
looking for some clarification:
1. $11.9 million in liabilities
One of your previous posts: #8850 on 6/20/2019
"over 600 million fresh shares of NSPX shares need to be issued to
cover debt and conversion obligations"
-------------------------
at the current average PPS, about 0.004 since 6/20/2019, that would be
about $2.4 million
***Where are you getting $11.9 million in liabilities from?
2. No way to pay it back
-------------------------
this is a Bio/Pharm in the beginning phase of something potentially
beyond comprehension of anyone playing in the OTC.
of course they have limited funds and are hurting for cash.
3. Non-complaint share structure which cannot be resolved as an SEC delinquent filer
---------------------------
What has NSPX been doing the last several months?
You cant expect them to put out 2 years worth of updates with their limited financial capabilities in a short period of time.
I for one was hoping for the July 5th date but was not shaken when they missed the deadline.
$NSPX STRONG